Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily secreted by hepatocytes. PCSK9 is critical in liver low-density lipoprotein receptors (LDLRs) metabolism. In addition to its hepatocellular presence, PCSK9 has also been detected in cardiac, cerebral, islet, renal, adipose, and other...
Saved in:
Main Authors: | Fengyuan Lu (Author), En Li (Author), Xiaoyu Yang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease
by: Eun Ji Kim, et al.
Published: (2020) -
Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease
by: Bianca E. Suur, et al.
Published: (2022) -
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
by: Vittoria Cammisotto, et al.
Published: (2022) -
The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process - is there a link?
by: Malwina Grobelna, et al.
Published: (2019) -
Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review
by: Wei C. Yuet, et al.
Published: (2021)